Trial-Results center  
Clinical trial results database Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

heart failure - antithrombotics - all type of patients


Related trials

RE-NOVATE 2, 2010 - dabigatran 220mg vs enoxaparin

ADVANCE 2 (CV185-047), 2010 - apixaban vs enoxaparin

WATCH (warfarin vs aspirin), 2009 - warfarin vs aspirin

RECORD 4, 2009 - rivaroxaban vs enoxaparin

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin

RECORD 2, 2008 - extended rivaroxaban vs enoxaparin

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin

ADVANCE-1, 2008 - apixaban vs enoxaparin

RECORD 1, 2008 - extended rivaroxaban vs extended enoxaparin

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin

HELAS (warfarin vs aspirin), 2006 - warfarin vs aspirin

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin

HELAS (warfarin vs placebo), 2006 - warfarin vs placebo

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin

BISTRO II (225mg bid), 2005 - dabigatran 450mg vs enoxaparin

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose

WASH (aspirin), 2004 - aspirin vs no treatment

WASH (warfarin), 2004 - warfarin vs no treatment

PATAF (coumadin low dose vs coumadin standard dose), 1999 - coumadin low dose vs coumadin standard dose

AFASAK II (warfarin low dose vs warfarin standard dose), 1998 - warfarin low dose vs warfarin standard dose



See also:

  • All heart failure clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of warfarin
    		•  

    WATCH (warfarin vs aspirin) study, 2009

    [NCT00007683] Facebook    pdf : warfarin - antithrombotics for heart failure

    Treatments

    Studied treatment warfarin (target INR 2.5-3.0)
    Control treatment aspirin 162 mg daily

    Patients

    Patients symptomatic heart failure patients in sinus rhythm with ejection fractions 35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics

    Method and design

    Randomized effectives 540 / 523 (studied vs. control)
    Design Parallel groups
    Blinding open
    Primary endpoint death from all causes, nonfatal


    Results

    No results available for this trial - no clinical endpoint reported

    Meta-analysis of all similar trials:

    antithrombotics in heart failure for all type of patients



    Reference(s)

    Trials register # NCT00007683
    • Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S, . The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.. J Card Fail 2004;10:101-12.
      Pubmed | Hubmed | Fulltext
    • Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.. Circulation 2009 Mar 31;119:1616-24
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend